XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.25.2

Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Accounting Policies [Abstract] |
Percentage of Net Product Sales and Accounts Receivable Balance | The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:
|  | Net Product Sales |  |  | Accounts Receivable |
|  | Three Months Ended June 30, 2025 |  |  | Six Months Ended June 30, 2025 |  |  | As of June 30, 2025 |
Customer A |  |  | 44.2 | % |  |  | 43.9 | % |  |  | 43.8 | %
Customer B |  |  | 33.9 | % |  |  | 33.5 | % |  |  | 34.4 | %
Customer C |  |  | 20.4 | % |  |  | 21.2 | % |  |  | 21.3 | %
Total |  |  | 98.5 | % |  |  | 98.6 | % |  |  | 99.5 | %
Schedule of Disaggregated Net Product Sales | The following table provides disaggregated net product sales (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
CINVANTI net product sales |  | $ | 24,143 |  |  | $ | 24,927 |  |  | $ | 49,886 |  |  | $ | 50,544 |
SUSTOL net product sales |  |  | 2,404 |  |  |  | 4,246 |  |  |  | 5,263 |  |  |  | 7,860 |
ZYNRELEF net product sales |  |  | 8,189 |  |  |  | 5,831 |  |  |  | 16,230 |  |  |  | 10,844 |
APONVIE net product sales |  |  | 2,464 |  |  |  | 1,020 |  |  |  | 4,724 |  |  |  | 1,446 |
Total net product sales |  | $ | 37,200 |  |  | $ | 36,024 |  |  | $ | 76,103 |  |  | $ | 70,694 |
Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees | The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):
|  | Product Returns |  |  | Distributor Fees |  |  | Discounts, Rebates and Administrative Fees |  |  | Total |
Balance at December 31, 2024 |  | $ | 3,791 |  |  | $ | 5,883 |  |  | $ | 27,745 |  |  | $ | 37,419 |
Provision |  |  | 962 |  |  |  | 17,188 |  |  |  | 114,605 |  |  |  | 132,755 |
Payments/credits |  |  | (472 | ) |  |  | (17,028 | ) |  |  | (112,621 | ) |  |  | (130,121 | )
Balance at June 30, 2025 |  | $ | 4,281 |  |  | $ | 6,043 |  |  | $ | 29,729 |  |  | $ | 40,053 |
Schedule of Numerator (Earnings or Loss) and Denominator (Weighted-Average Number of Common Shares Outstanding for Period, Including Pre-funded Warrants) to Calculate the Basic and Diluted Earnings Per Share | The computations of the numerator (earnings or loss) and denominator (weighted-average number of common shares outstanding for the period, including pre-funded warrants) to calculate the basic and diluted earnings per share amounts presented in the accompanying condensed consolidated statements of operations and comprehensive (loss) income are as follows (in thousands, except per share amounts):
|  | Three Months Ended June 30, 2025 |  |  | Three Months Ended June 30, 2024 |  |  | Six Months Ended June 30, 2025 |  |  | Six Months Ended June 30, 2024 |
|  | Income |  |  | Shares |  |  | Income |  |  | Shares |  |  | Income |  |  | Shares |  |  | Income |  |  | Shares |
Basic: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net (loss) income |  | $ | (2,381 | ) |  |  | 154,020 |  |  | $ | (9,235 | ) |  |  | 152,305 |  |  | $ | 254 |  |  |  | 153,804 |  |  | $ | (12,395 | ) |  |  | 151,900 |
(Loss) earnings per share, basic |  | $ | (0.02 | ) |  |  |  |  | $ | (0.06 | ) |  |  |  |  | $ | 0.00 |  |  |  |  |  | $ | (0.08 | ) |  |  |
Diluted: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net (loss) income |  | $ | (2,381 | ) |  |  | 154,020 |  |  | $ | (9,235 | ) |  |  | 152,305 |  |  | $ | 254 |  |  |  | 153,804 |  |  | $ | (12,395 | ) |  |  | 151,900 |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 29,697 |  |  |  | — |  |  |  | — |
Restricted stock units outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,133 |  |  |  | — |  |  |  | — |
Warrants outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 298 |  |  |  | — |  |  |  | — |
Shares of common stock underlying convertible notes outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 9,819 |  |  |  | — |  |  |  | — |
Net (loss) income, diluted |  | $ | (2,381 | ) |  |  | 154,020 |  |  | $ | (9,235 | ) |  |  | 152,305 |  |  | $ | 254 |  |  |  | 197,751 |  |  | $ | (12,395 | ) |  |  | 151,900 |
(Loss) earnings per share, diluted |  | $ | (0.02 | ) |  |  |  |  | $ | (0.06 | ) |  |  |  |  | $ | 0.00 |  |  |  |  |  | $ | (0.08 | ) |  |  |
Common Stock Equivalents Excluded From Computation of Net Loss Per Share | Because we incurred a net loss for the three months ended June 30, 2025 and the three and six months ended June 30, 2024, the following common stock equivalents were not included in the computation of earnings per share because their effect would be anti-dilutive (in thousands):
|  | June 30, |
|  | 2025 |  |  | 2024 |
Stock options outstanding |  |  | 29,697 |  |  |  | 27,445 |
Restricted stock units outstanding |  |  | 4,133 |  |  |  | 1,642 |
Warrants outstanding |  |  | 298 |  |  |  | 298 |
Shares of common stock underlying convertible notes outstanding |  |  | 9,819 |  |  |  | 9,819 |

X
- Definition Schedule of disaggregated net product sales. + References No definition available. + Details
Name: | hrtx_ScheduleOfDisaggregatedNetProductSalesTableTextBlock
Namespace Prefix: | hrtx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs. + References No definition available. + Details
Name: | hrtx_ValuationAllowancesAndReservesTableTextBlock
Namespace Prefix: | hrtx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration